Immunology of osteoporosis: relevance of inflammatory targets for the development of novel interventions

Papers of special note have been highlighted as: • of interest

References

• 1. Okamoto K, Nakashima T, Shinohara M et al. Osteoimmunology: the conceptual framework unifying the immune and skeletal systems. Physiol. Rev. 97(4), 1295–1349 (2017).
  Medline CASGoogle Scholar
• 2. Das S, Crockett JC. Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des. Devel. Ther. 7, 435–448 (2013).
  Medline CASGoogle Scholar
• 3. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 377(9773), 1276–1287 (2011).
  Medline CASGoogle Scholar
• 4. Geusens P, Lems WF. Osteoimmunology and osteoporosis. Arthritis Res. Ther. 13(5), 1–16 (2011).
  Google Scholar
• 5. Srivastava RK, Dar HY, Mishra PK. Immunoporosis: immunology of osteoporosis-role of T cells. Front. Immunol. 9, 657 (2018).
  MedlineGoogle Scholar
• 6. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7(6), 429–442 (2007).
  Medline CASGoogle Scholar
• 7. Weitzmann MN. The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis. Scientifica (Cairo) 2013, 1–29 (2013).
  Google Scholar
• 8. Proff P, Römer P. The molecular mechanism behind bone remodelling: a review. Clin. Oral Investig. 13(4), 355–362 (2009).
  MedlineGoogle Scholar
• 9. DW B, GA D. Bone biology and physiology: Part I. The fundamentals. Plast. Reconstr. Surg. 129(6), 1314–1320 (2012).
  MedlineGoogle Scholar
• 10. Clarke BL, Khosla S. Physiology of bone loss. Radiol. Clin. North Am. 48(3), 483–495 (2010).
  MedlineGoogle Scholar
• 11. Karsenty G, Kronenberg HM, Settembre C. Genetic control of bone formation. Annu. Rev. Cell Dev. Biol. 25, 629–648 (2009).
  Medline CASGoogle Scholar
• 12. Katsimbri P. The biology of normal bone remodelling. Eur. J. Cancer Care (Engl.) 26(6), (2017).
  MedlineGoogle Scholar
• 13. Clarke B. Normal bone anatomy and physiology. Clin. J. Am. Soc. 3, 131–139 (2008).
  Google Scholar
• 14. Rochefort G, Pallu S, Benhamou CL. Osteocyte: the unrecognized side of bone tissue. Osteoporos. Int. 21(9), 1457–1469 (2010).
  Medline CASGoogle Scholar
• 15. Ross FP, Teitelbaum SL. αvβ3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol. Rev. 208, 88–105 (2005).
  Medline CASGoogle Scholar
• 16. Boyle W, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 423(6937), 337–342 (2003).
  Medline CASGoogle Scholar
• 17. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res. Ther. 9(Suppl. 1), S1 (2007).
  MedlineGoogle Scholar
• 18. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25(3), 255–259 (1999).
  Medline CASGoogle Scholar
• 19. Hadjidakis DJ, Raptis AE, Sfakianakis M, Mylonakis A, Raptis SA. Bone mineral density of both genders in Type 1 diabetes according to bone composition. J. Diabetes Complications 20(5), 302–307 (2006).
  MedlineGoogle Scholar
• 20. Mangashetti LS, Khapli SM, Wani MR. IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-κB and Ca 2+ signaling. J. Immunol. 175(2), 917–925 (2005).
  Medline CASGoogle Scholar
• 21. Yun TJ, Chaudhary PM, Shu GL et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J. Immunol. 161(11), 6113–6121 (1998).
  Medline CASGoogle Scholar
• 22. Wing K, Yamaguchi T, Sakaguchi S. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol. 32(9), 428–433 (2011).
  Medline CASGoogle Scholar
• 23. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat. Rev. Immunol. 2(12), 933–944 (2002).
  Medline CASGoogle Scholar
• 24. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat. Rev. Rheumatol. 5(12), 667–676 (2009).
  Medline CASGoogle Scholar
• 25. Sims NA, Green JR, Glatt M et al. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum. 50(7), 2338–2346 (2004).
  Medline CASGoogle Scholar
• 26. Sato K, Suematsu A, Okamoto K et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203(12), 2673–2682 (2006).
  Medline CASGoogle Scholar
• 27. Krause DS. Regulation of hematopoietic stem cell fate. Oncogene 21(21), 3262–3269 (2002).
  Medline CASGoogle Scholar
• 28. Boyce BF Xing L. The RANKL/RANK/OPG pathway. Curr. Osteoporos. Rep. 5(3), 98–104 (2007).
  MedlineGoogle Scholar
• 29. Rubin J, Ackert-Bicknell CL, Zhu L et al. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand in vitro and OPG in vivo. J. Clin. Endocrinol. Metab. 87(9), 4273–4279 (2002).
  Medline CASGoogle Scholar
• 30. Bengtsson AK, Ryan EJ. Immune function of the decoy receptor osteoprotegerin. Crit. Rev. Immunol. 22(3), 15 (2002).
  Google Scholar
• 31. Breuil V, Ticchioni M, Testa J et al. Immune changes in post-menopausal osteoporosis: the Immunos study. Osteoporos. Int. 21(5), 805–814 (2010).
  Medline CASGoogle Scholar
• 32. Andersen TL, Sondergaard TE, Skorzynska KE et al. A Physical mechanism for coupling bone resorption and formation in adult human bone. Am. J. Pathol. 174(1), 239–247 (2009).
  Medline CASGoogle Scholar
• 33. Hill PA. Bone remodelling. Br. J. Orthod. 25(2), 101–107 (1998).
  Medline CASGoogle Scholar
• 34. Bonewald LF. Osteocytes as dynamic multifunctional cells. Ann. NY Acad. Sci. 1116, 281–290 (2007).
  Medline CASGoogle Scholar
• 35. Ma Q, Ma Z, Liang M et al. The role of physical forces in osteoclastogenesis. J. Cell. Physiol. 234(8), 12498–12507 (2019).
  Medline CASGoogle Scholar
• 36. Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem. 285(33), 25103–25108 (2010). • Specifically discusses the immunological aspect of bone remodeling.
  Medline CASGoogle Scholar
• 37. Heino TJ, Hentunen TA, Väänänen HK. Osteocytes inhibit osteoclastic bone resorption through transforming growth factor-β: enhancement by estrogen. J. Cell. Biochem. 85(1), 185–197 (2002).
  Medline CASGoogle Scholar
• 38. Juppner H, Abou-Samra A, Freeman M et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254(5034), 1024–1026 (1991).
  Medline CASGoogle Scholar
• 39. Swarthout JT, D'Alonzo RC, Selvamurugan N, Partridge NC. Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. Gene 282(1–2), 1–17 (2002).
  Medline CASGoogle Scholar
• 40. Li X, Qin L, Bergenstock M, Bevelock LM, Novack DV, Partridge NC. Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts. J. Biol. Chem. 282(45), 33098–33106 (2007).
  Medline CASGoogle Scholar
• 41. Canalis E. Management of endocrine disease: novel anabolic treatments for osteoporosis. Eur. J. Endocrinol. 178(2), R33–R44 (2018).
  Medline CASGoogle Scholar
• 42. Everts V, Delaissé JM, Korper W et al. The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. J. Bone Miner. Res. 17(1), 77–90 (2002).
  Medline CASGoogle Scholar
• 43. Heinemann DEH, Siggelkow H, Ponce LM, Viereck V, Wiese KG, Peters JH. Alkaline phosphatase expression during monocyte differentiation overlapping markers as a link between monocytic cells, dendritic cells, osteoclasts and osteoblasts. Immunobiology 202(1), 68–81 (2000).
  Medline CASGoogle Scholar
• 44. Takahashi F, Takahashi K, Shimizu K et al. Osteopontin is strongly expressed by alveolar macrophages in the lungs of acute respiratory distress syndrome. Lung 182(3), 173–185 (2004).
  Medline CASGoogle Scholar
• 45. Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler. Thromb. Vasc. Biol. 28(12), 2108–2114 (2008).
  Medline CASGoogle Scholar
• 46. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc. Natl Acad. Sci. USA 105(52), 20764–20769 (2008).
  Medline CASGoogle Scholar
• 47. Zhao C, Irie N, Takada Y et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 4(2), 111–121 (2006).
  Medline CASGoogle Scholar
• 48. van Bezooijen RL, Roelen BAJ, Visser A et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 199(6), 805–814 (2004).
  Medline CASGoogle Scholar
• 49. Sun L, Blair HC, Peng Y et al. Calcineurin regulates bone formation by the osteoblast. Proc. Natl Acad. Sci. USA 102(47), 17130–17135 (2005).
  Medline CASGoogle Scholar
• 50. Robling AG, Niziolek PJ, Baldridge LA et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of sost/sclerostin. J. Biol. Chem. 283(9), 5866–5875 (2008).
  Medline CASGoogle Scholar
• 51. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J. Mol. Med. 83(3), 170–179 (2005).
  Medline CASGoogle Scholar
• 52. Walsh MC, Kim N, Kadono Y et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu. Rev. Immunol. 24, 33–63 (2006).
  Medline CASGoogle Scholar
• 53. Yeo L, Toellner KM, Salmon M et al. Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann. Rheum. Dis. 70(11), 2022–2028 (2011).
  Medline CASGoogle Scholar
• 54. Troen BR. Molecular mechanisms underlying osteoclast formation and activation. Exp. Gerontol. 38(6), 605–614 (2003).
  Medline CASGoogle Scholar
• 55. Katagiri T, Takahashi N. Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis. 8(3), 147–159 (2002).
  Medline CASGoogle Scholar
• 56. Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem. Biophys. Res. Commun. 256(3), 449–455 (1999).
  Medline CASGoogle Scholar
• 57. Sirufo MM, Suppa M, Ginaldi L, De Martinis M. Does allergy break bones? Osteoporosis and its connection to allergy. Int. J. Mol. Sci. 21(3), 712 (2020).
  CASGoogle Scholar
• 58. Ross B, Krapp S, Augustin M et al. Structures and mechanism of dipeptidyl peptidases 8 and 9, important players in cellular homeostasis and cancer. Proc. Natl Acad. Sci. USA 115(7), E1437–E1445 (2018).
  Medline CASGoogle Scholar
• 59. Roy B. Biomolecular basis of the role of diabetes mellitus in osteoporosis and bone fractures. World J. Diabetes 4(4), 101 (2013).
  MedlineGoogle Scholar
• 60. Miura M, Tanaka K, Komatsu Y et al. A novel interaction between thyroid hormones and 1,25(OH)2D3 in osteoclast formation. Biochem. Biophys. Res. Commun. 291(4), 987–994 (2002).
  Medline CASGoogle Scholar
• 61. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 140(8), 3552–3561 (1999).
  Medline CASGoogle Scholar
• 62. Chung H, Kang YS, Hwang CS et al. Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. J. Korean Med. Sci. 16(6), 769–773 (2001).
  Medline CASGoogle Scholar
• 63. Kikuchi T, Matsuguchi T, Tsuboi N et al. Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via toll-like receptors. J. Immunol. 166(5), 3574–3579 (2001).
  Medline CASGoogle Scholar
• 64. Deyama Y, Kikuiri T, Ohnishi GI et al. Histamine stimulates production of osteoclast differentiation factor/receptor activator of nuclear factor-κB ligand by osteoblasts. Biochem. Biophys. Res. Commun. 298(2), 240–246 (2002).
  Medline CASGoogle Scholar
• 65. Chikazu D, Katagiri M, Ogasawara T et al. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor functi. J. Bone Miner. Res. 16(11), 2074–2081 (2001).
  Medline CASGoogle Scholar
• 66. Takai H, Kanematsu M, Yano K et al. Transforming growth factor-β stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J. Biol. Chem. 273(42), 27091–27096 (1998).
  Medline CASGoogle Scholar
• 67. Kim JH, Kim N. Regulation of NFATc1 in osteoclast differentiation. J. Bone Metab. 21, 233–241 (2014).
  MedlineGoogle Scholar
• 68. Timlin M, Toomey D, Condron C. Fracture hematoma is a potent proinflammatory mediator of neutrophil function background: patients with multiple. J. Trauma Inj. Infect. Crit. Care 58(6), 1223–1229 (2005).
  MedlineGoogle Scholar
• 69. Ponzetti M, Rucci N. Updates on osteoimmunology: what's new on the cross-talk between bone and immune system. Front. Endocrinol. (Lausanne) 10, 1–13 (2019).
  MedlineGoogle Scholar
• 70. De Matos CT, Berg L, Michaëlsson J, Felländer-Tsai L, Kärre K, Söderström K. Activating and inhibitory receptors on synovial fluid natural killer cells of arthritis patients: role of CD94/NKG2A in control of cytokine secretion. Immunology 122(2), 291–301 (2007).
  MedlineGoogle Scholar
• 71. Mortaz E, Alipoor SD, Adcock IM, Mumby S, Koenderman L. Update on neutrophil function in severe inflammation. Front. Immunol. 9, 2171 (2018).
  MedlineGoogle Scholar
• 72. Pietschmann P, Mechtcheriakova D, Meshcheryakova A, Föger-Samwald U, Ellinger I. Immunology of osteoporosis: a mini-review. Gerontology 62(2), 128–137 (2016).
  Medline CASGoogle Scholar
• 73. Park SH, Silva M, Bahk WJ, McKellop H, Lieberman JR. Effect of repeated irrigation and debridement on fracture healing in an animal model. J. Orthop. Res. 20(6), 1197–1204 (2002).
  MedlineGoogle Scholar
• 74. Hajishengallis G, Moutsopoulos NM, Hajishengallis E, Chavakis T. Immune and regulatory functions of neutrophils in inflammatory bone loss. Semin. Immunol. 28(2), 146–158 (2016).
  Medline CASGoogle Scholar
• 75. Katayama M, Ohmura K, Yukawa N et al. Neutrophils are essential as a source of Il-17 in the effector phase of arthritis. PLoS One 8(5), 62231 (2013).
  Google Scholar
• 76. Srivastava RK, Schmidt-Bleek K, Chattopadhyay N, De Martinis M, Mishra PK. Editorial: recent advances in basic and translational osteoimmunology. Front. Immunol. 12, 800508 (2021).
  Medline CASGoogle Scholar
• 77. Srivastava RK, Sapra L. The rising era of ‘immunoporosis’: role of immune system in the pathophysiology of osteoporosis. J. Inflamm. Res. 5(15), 1667–1698 (2022).
  Google Scholar
• 78. Murdaca G, Greco M, Tonacci A et al. Il-33/il-31 axis in immune-mediated and allergic diseases. Int. J. Mol. Sci. 20(23), 5856 (2019).
  CASGoogle Scholar
• 79. Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J. Clin. Cell. Immunol. 2(3), 110 (2011).
  MedlineGoogle Scholar
• 80. Zupan J, Jeras M, Marc J. Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclasts. Biochem Med (Zagreb) 23(1), 43–63 (2013).
  Medline CASGoogle Scholar
• 81. Renke J, Kędzierska-Mieszkowska S, Lange M et al. Mast cells in mastocytosis and allergy – important player in metabolic and immunological homeostasis. Adv. Med. Sci. 64(1), 124–130 (2019).
  MedlineGoogle Scholar
• 82. Ferencz V, Meszaros S, Csupor E et al. Increased bone fracture prevalence in postmenopausal women suffering from pollen-allergy. Osteoporos. Int. 17(3), 484–491 (2006).
  MedlineGoogle Scholar
• 83. Garla VV, Chaudhary KUQ, Yaqub A. Systemic mastocytosis: a rare cause of osteoporosis. Pan Afr. Med. J. 32, 169 (2019).
  MedlineGoogle Scholar
• 84. Rossini M, Zanotti R, Orsolini G et al. Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. Osteoporos. Int. 27(8), 2411–2421 (2016).
  Medline CASGoogle Scholar
• 85. Naito A, Azuma S, Tanaka S et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4(6), 353–362 (1999).
  Medline CASGoogle Scholar
• 86. Föger-Samwald U, Dovjak P, Azizi-Semrad U, Kerschan-Schindl K, Pietschmann P. Osteoporosis: pathophysiology and therapeutic options. EXCLI J. 19, 1017–1037 (2020).
  MedlineGoogle Scholar
• 87. Ferbebouh M, Vallières F, Benderdour M, Fernandes J. The pathophysiology of immunoporosis: innovative therapeutic targets. Inflamm. Res. 70(8), 859–875 (2021).
  Medline CASGoogle Scholar
• 88. Michalski MN, McCauley LK. Macrophages and skeletal health. Pharmacol. Ther. 174, 43–54 (2017).
  Medline CASGoogle Scholar
• 89. Li Y, Ling J, Jiang Q. Inflammasomes in alveolar bone loss. Front. Immunol. 12, 2130 (2021).
  Google Scholar
• 90. Li Y, Toraldo G, Li A et al. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 109(9), 3839–3848 (2007).
  Medline CASGoogle Scholar
• 91. Onal M, Xiong J, Chen X et al. Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J. Biol. Chem. 287(35), 29851–29860 (2012).
  Medline CASGoogle Scholar
• 92. D'Amelio P, Grimaldi A, Di Bella S et al. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone 43(1), 92–100 (2008).
  MedlineGoogle Scholar
• 93. Saxena Y, Routh S, Mukhopadhaya A. Immunoporosis: role of innate immune cells in osteoporosis. Front. Immunol. 12, 687037 (2021).
  Medline CASGoogle Scholar
• 94. Collin M, Bigley V. Human dendritic cell subsets: an update. Immunology 154(1), 3–20 (2018).
  Medline CASGoogle Scholar
• 95. Legge KL, Gregg RK, Maldonado-Lopez R et al. On the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunity. J. Exp. Med. 196(2), 217–227 (2002).
  Medline CASGoogle Scholar
• 96. Thomas R, MacDonald KPA, Pettit AR, Cavanagh LL, Padmanabha J, Zehntner S. Dendritic cells and the pathogenesis of rheumatoid arthritis. J. Leukoc. Biol. 66(2), 286–292 (1999).
  Medline CASGoogle Scholar
• 97. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 449(7161), 419–426 (2007).
  Medline CASGoogle Scholar
• 98. Izawa T, Ishimaru N, Moriyama K, Kohashi M, Arakaki R, Hayashi Y. Crosstalk between RANKLand Fas signaling in dendritic cells controls immune tolerance. Blood 110(1), 242–250 (2007).
  Medline CASGoogle Scholar
• 99. Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. Front. Immunol. 5, 511 (2014).
  MedlineGoogle Scholar
• 100. Ott C, Jacobs K, Haucke E, Navarrete Santos A, Grune T, Simm A. Role of advanced glycation end products in cellular signaling. Redox Biol. 2(1), 411–429 (2014).
  Medline CASGoogle Scholar
• 101. Vikulina T, Fan X, Yamaguchi M et al. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc. Natl Acad. Sci. USA 107(31), 13848–13853 (2010).
  Medline CASGoogle Scholar
• 102. Zhao E, Xu H, Wang L et al. Bone marrow and the control of immunity. Cell. Mol. Immunol. 9(1), 11–19 (2012).
  Medline CASGoogle Scholar
• 103. Kung YY, Felge U, Sarosi I et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402(6759), 304–309 (1999).
  MedlineGoogle Scholar
• 104. Dar HY, Singh A, Shukla P et al. High dietary salt intake correlates with modulated Th17-Treg cell balance resulting in enhanced bone loss and impaired bone-microarchitecture in male mice. Sci. Rep. 8(1), 2503 (2018).
  MedlineGoogle Scholar
• 105. Huber S, Gagliani N, O'Connor W, Geginat J, Caprioli F. CD4+ T helper cell plasticity in infection, inflammation, and autoimmunity. Mediators Inflamm. 2017, 7083153 (2017).
  MedlineGoogle Scholar
• 106. Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine 74(1), 5–17 (2015).
  Medline CASGoogle Scholar
• 107. Palmqvist P, Lundberg P, Persson E et al. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J. Biol. Chem. 281(5), 2414–2429 (2006).
  Medline CASGoogle Scholar
• 108. Pacifici R. T cells: critical bone regulators in health and disease. Bone 47(3), 461–471 (2010).
  Medline CASGoogle Scholar
• 109. Schmitt E, Klein M, Bopp T. Th9 cells new players in adaptive immunity. Trends Immunol. 35(2), 61–68 (2014).
  Medline CASGoogle Scholar
• 110. Locksley RM. Nine lives: plasticity among T helper cell subsets. J. Exp. Med. 206(8), 1643–1646 (2009).
  Medline CASGoogle Scholar
• 111. Dar HY, Azam Z, Anupam R, Mondal RK, Srivastava RK. Osteoimmunology: the nexus between bone and immune system. Front. Biosci. (Landmark Ed.) 23(3), 464–492 (2018).
  Medline CASGoogle Scholar
• 112. Ciucci T, Ibáñez L, Boucoiran A et al. Bone marrow Th17 TNFα cells induce osteoclast differentiation, and link bone destruction to IBD. Gut 64(7), 1072–1081 (2015).
  Medline CASGoogle Scholar
• 113. Adamopoulos IE, Chao C chi, Geissler R et al. Interleukin-17A upregulates receptor activator of NF-κB on osteoclast precursors. Arthritis Res. Ther. 12(1), R29 (2010).
  MedlineGoogle Scholar
• 114. Yu M, Cavero V, Lu Q, Li H. Follicular helper T cells in rheumatoid arthritis. Clin. Rheumatol. 34(9), 1489–1493 (2015).
  MedlineGoogle Scholar
• 115. Cooley S, Parham P, Miller JS. Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. Blood 131(10), 1053–1062 (2018).
  Medline CASGoogle Scholar
• 116. Fujii SI, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by α galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198(2), 267–279 (2003).
  Medline CASGoogle Scholar
• 117. Tilkeridis K, Kiziridis G, Ververidis AB et al. Immunoporosis: a new role for invariant natural killer T (NKT) cells through overexpression of nuclear factor-kB ligand (RANKL). Med. Sci. Monit. 2151–2158 (2019).
  MedlineGoogle Scholar
• 118. Shashkova EV, Trivedi J, Cline-Smith AB et al. Osteoclast-primed Foxp3 + CD8 T cells induce T-bet, eomesodermin, and IFN-γ to regulate bone resorption. J. Immunol. 197(3), 726–735 (2016).
  Medline CASGoogle Scholar
• 119. Murad MH, Drake MT, Mullan RJ et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J. Clin. Endocrinol. Metab. 97(6), 1871–1880 (2012).
  Medline CASGoogle Scholar
• 120. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356(18), 1809–1822 (2007).
  Medline CASGoogle Scholar
• 121. Cummings SR, San Martin J, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361(8), 756–765 (2009).
  Medline CASGoogle Scholar
• 122. Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J. Steroid Biochem. Mol. Biol. 142, 155–170 (2014).
  Medline CASGoogle Scholar
• 123. Deeks ED. Denosumab: a review in postmenopausal osteoporosis. Drugs Aging 35(2), 163–173 (2018).
  Medline CASGoogle Scholar
• 124. Cosman F, Crittenden DB, Ferrari S et al. FRAME Study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J. Bone Miner. Res. 33(7), 1219–1226 (2018).
  Medline CASGoogle Scholar
• 125. Tian A, Jia H, Zhu S et al. Romosozumab versus teriparatide for the treatment of postmenopausal osteoporosis: a systematic review and meta-analysis through a grade analysis of evidence. Orthop. Surg. 13(7), 1941–1950 (2021).
  MedlineGoogle Scholar
• 126. Geusens P, Feldman R, Oates M et al. Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis. Bone 154, 116209 (2022).
  Medline CASGoogle Scholar
• 127. Saag KG, Petersen J, Brandi ML et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N. Engl. J. Med. 377(15), 1417–1427 (2017).
  Medline CASGoogle Scholar
• 128. MacNabb C, Patton D, Hayes JS. Sclerostin antibody therapy for the treatment of osteoporosis: clinical prospects and challenges. J. Osteoporos. 2016, 6217286 (2016).
  MedlineGoogle Scholar
• 129. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 26(1), 19–26 (2011).
  Medline CASGoogle Scholar
• 130. Recknor CP, Recker RR, Benson CT et al. The effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density. J. Bone Miner. Res. 30(9), 1717–1725 (2015).
  Medline CASGoogle Scholar
• 131. Reid IR. Targeting sclerostin in postmenopausal osteoporosis: focus on romosozumab and blosozumab. BioDrugs 31(4), 289–297 (2017).
  Medline CASGoogle Scholar
• 132. Glorieux FH, Devogelaer JP, Durigova M et al. BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial. J. Bone Miner. Res. 32(7), 1496–1504 (2017).
  Medline CASGoogle Scholar
• 133. Lewiecki EM. Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Ther. Adv. Musculoskelet. Dis. 6(2), 48–57 (2014).
  Medline CASGoogle Scholar
• 134. Novartis. Novartis Clinical Innovations Pipeline Annual Report (2014). https://prod.arctic.novartis.com/sites/novartis_com/files/novartis-annual-report-2014-en.pdf
  Google Scholar
• 135. Fulciniti M, Tassone P, Hideshima T et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114(2), 371–379 (2009).
  Medline CASGoogle Scholar
• 136. Goldhahn J, Féron JM, Kanis J et al. Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif. Tissue Int. 90(5), 343–353 (2012).
  Medline CASGoogle Scholar
• 137. Iyer SP, Beck JT, Stewart AK et al. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br. J. Haematol. 167(3), 366–375 (2014).
  Medline CASGoogle Scholar
• 138. Boumpas DT, Furie R, Manzi S et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48(3), 719–727 (2003).
  Medline CASGoogle Scholar
• 139. Murata K, Nose M, Ndhlovu LC, Sato T, Sugamura K, Ishii N. Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. J. Immunol. 169(8), 4628–4636 (2002).
  Medline CASGoogle Scholar
• 140. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 3(8), 609–620 (2003).
  Medline CASGoogle Scholar
• 141. Lippuner K. The future of osteoporosis treatment - a research update. Swiss Med. Wkly 142, w13624 (2012).
  MedlineGoogle Scholar
• 142. Hsu YH, Chen WY, Chan CH, Wu CH, Sun ZJ, Chang MS. Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. J. Exp. Med. 208(9), 1849–1861 (2011).
  Medline CASGoogle Scholar
• 143. Hsu YH, Chiu YS, Chen WY et al. Anti-IL-20 monoclonal antibody promotes bone fracture healing through regulating IL-20-mediated osteoblastogenesis. Sci. Rep. 6, 24339 (2016).
  Medline CASGoogle Scholar
• 144. Gauthier JY, Chauret N, Cromlish W et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg. Med. Chem. Lett. 18(3), 923–928 (2008).
  Medline CASGoogle Scholar
• 145. McClung MR, O'Donoghue ML, Papapoulos SE et al. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes Endocrinol. 7(12), 899–911 (2019).
  Medline CASGoogle Scholar